A clean laser focused Company
The simplest but most relevant analysis you will find on the Company. Read slowly, think carefully & you might agree !.... Do comment at the end for any clarification/ views.
Information last updated - June 29, 2020
Summary
Decent long term compounding story.
Sector Interest
😘 Flavor of the season.
Financials
🙂 Decent business growth, stable margins, ok cash generation. Low debt.
Technicals
🙂 Long term chart broken out in Jan 20 and retested the breakout in Mar and May 20
Management
🙂 Good promoter driven Company with a solid professional board.
Valuation
🙂 Closer to the lower end of historical valuation band.
Investor Interest
🙂 Decent. Institutions have been accumulating from public.
SWOT
Strengths
- Amongst top ten pharma companies in India
- Leadership position in anti infectives segment
- Able management with strong professional board
- Low net debt levels
- Consistent business growth and stable margins
Weaknesses
- Significant (40%) business is from overseas
- Cash flow from operations are volatile vis-a-vis business growth and margins
- Valuations are not overly attractive
Threats
- Disruptions caused due to Covid2019. Surgeries are postponed impacting Company's anti infectives
- Regulatory approvals
Opportunities
- Improving performance in the chronic therapy segments like Neuro / CNS, Derma and Anti-Diabetes
- Significantly growing Vitamins/ Minerals / Nutrients segment. This segment shall continue to find more and more acceptance in the post Covid2019 world
- As on March 31, 2020, the Company has filed a total of 144 ANDAs (including 2 NDA) with the US FDA and has received 89 approvals (including 13 tentative approvals and 2NDAs)
Management Quality
- Alkem is currently run by Sandeep Singh (MD). He is from the promoter family and is associated with the Company since 2003.
- Based on my reading so far, he seems reasonable and well regarded.
- The pedigree of people on the Board further testifies towards the corporate governance standards at the Company.
Financials
Auditors - B S R & Co. LLP
Bankers - Citi, HDFC, HSBC, Kotak Mahindra, SBI & others
Credit Rating - Crisil (AA+ Stable, A1+), Fitch - IND A1+
- Company has a strong credit rating
- Revenues have grown consistently though with higher base the rate of growth is slowing down
- Margins are stable and return on capital is good
- Cash flow from operations have got hit in the current year but that maybe because of COVID2019 impact. I will be watching this very closely.
- Debt levels are comfortable
- Valuations are neither too low nor too high. From current levels, upside potential is more than significant downside risk. (Note: March 20 valuations are calculated at Rs 2,282/ share. Accordingly, please adjust the same as per current market price)
Important Links
Old Analysis
Other Important Observations​
– NA
Long Term Chart - a key parameter to understand the true nature of any Company
- Company seems to be a decent performer and currently retesting it’s previous breakout levels.
Interactive Chart & Current Technicals
List of All Analyzed Companies
Companies
Pharmaceutical generics, formulations and neutraceutricals
Rebooting the energies
You can love it, you can hate it but you cannot ignore it !
A Colourful play on economic revival… will it become your portfolio’s raunak?
Hope that it keeps plugging in
Keeps your spirit high !
inves4 Model Portfolio
An actively managed portfolio - cross between fundamental and technical analysis
- select companies - controlled risk - regular profit booking
Click for details
Relevant News/ Insights​
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adultage groups in Phase 2 trial Adjuvanted recombinant…
Over 300 pharma, healthcare companies eligible for new Covid loans
As many as 354 Crisil-rated companies, predominantly pharmaceutical firms and hospitals, with an aggregate bank exposure of Rs 40,000 crore…
Vaccitech, startup behind Oxford Covid vaccine tech, falls 20% in Nasdaq debut
American depositary shares of Vaccitech fell nearly 20% in their Nasdaq debut on Friday, giving the co-inventor of the Covid-19…
Stocks: When to sell? - Part 1
The most difficult and confusing topic in stock investing !
COVID2019 and stock investing – Part 4 – is it a blessing in disguise for the Indian economy !
At first read, the presented arguments may sound counter intuitive. However, think carefully and you might agree.
Is it time to buy the Indian midcaps – Update December 31, 2019
4th note in the series... the last one for calendar year 2019 !
Disclaimer: The information presented above is no advice/ recommendation. Please do your own independent research before taking any investment related decision.
Good and simple
Thanks Kavinder.
Easy to understand .
Thanks 🙂
Congrats to Inves4 for completing a year and wishing a long and successful journey ahead.
Really liked the lucid company review (Alkem) that you have posted.
The Summary, SWOT, analysis of Long term charts etc were quite useful in getting a comprehensive view of the Co.
Thanks Kartik. Glad that you liked and found it useful. Look forward to continue offering simplistic analysis 🙂